Navigation Links
Pharmos Corporation Reports 2010 Third Quarter Results
Date:10/27/2010

tionPharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development is Dextofisopam for the treatment of IBS which has been developed through Phase 2b clinical trials. The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. These are available for licensing / partnering. www.pharmoscorp.com

Safe Harbor StatementStatements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.  Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.PHARMOS CORPORATIONCondensed Consolidated Statements of OperationsThree months endedSeptember 30,Nine months endedSeptember 30,2010200920102009ExpensesResearch and development

$  153,806$  1,047,260$  380,164$  4,266,337In-process research & development Vela milestone

---1,
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
2. Pharmos Issues Business Update on Dextofisopam Trial and Financing
3. Pharmos Corporation Reports 2009 Third Quarter Results
4. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. CEL-SCI Corporation Releases Letter to Shareholders
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
11. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... and TORONTO ... Corporation ( www.generex.com ) (OTCQB: GNBT) today ... implement a buccal cannabis co-development arrangement with ... been formalized. Generex and CannScience ... Technology Licensing Agreement.  Pursuant to the Agreement, ...
(Date:9/2/2015)... DIEGO , Sept. 2, 2015  MEI Pharma, ... on the clinical development of novel therapies for cancer, ... 30, 2015. Logo - http://photos.prnewswire.com/prnh/20140805/133834 ... fiscal year, I am quite pleased with how the ... Daniel P. Gold , Ph.D., President and Chief Executive ...
(Date:9/2/2015)... , Sept. 2, 2015 Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced today ... at both the FBR Second Annual Healthcare Conference and ... follows: FBR Second Annual Healthcare Conference ... Boston No presentation, investor meetings ...
Breaking Medicine Technology:Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3MEI Pharma Reports Fiscal Year 2015 Results 2MEI Pharma Reports Fiscal Year 2015 Results 3MEI Pharma Reports Fiscal Year 2015 Results 4MEI Pharma Reports Fiscal Year 2015 Results 5MEI Pharma Reports Fiscal Year 2015 Results 6MEI Pharma Reports Fiscal Year 2015 Results 7Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2
... 31, 2011 With the latest round of flu ... investigating the association between vaccines and febrile seizures in ... pulled over their eyes" about vaccines? It,s time for ... Big Pharma and the medical industry.   ...
... China Medical Technologies, Inc. (the "Company") (Nasdaq: ... company, today announced that it will report its unaudited ... 31, 2010 before the U.S. market opens on February ... March 31, 2011. The Company,s senior ...
Cached Medicine Technology:New Monograph Spotlights Urgent Need for Congress to Get Neurotoxins and Other Poisons Out of Vaccines 2China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011 2
(Date:9/2/2015)... ... ... The medical waste management market is expected to reach USD 13.3 billion ... global medical waste management market is segmented based on type of waste, services, treatment ... the highest growth rate in the medical waste management market, by service, during the ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... combining both naturopathic and allopathic medicine, opens its second location this week at ... features roughly 1000 square feet of lounge space for patients to relax while ...
(Date:9/2/2015)... ... September 02, 2015 , ... Every year at this time, students prepare ... few are prepared to face the academic workload confronting them. They just don’t have ... them since schools don’t teach students how to study. , “Bankers bank. Salesmen sell. ...
(Date:9/2/2015)... & Minneapolis, MN (PRWEB) , ... September 02, ... ... that is commercializing products for the upper extremity surgical market, announced today that ... surgical instrument for trigger releases in the hand. Plus, nearly 70 of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to bring awareness to International Overdose Awareness Day. The goal is to provide ... the warning signs so that they may get help. , Lakeview ...
Breaking Medicine News(10 mins):Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 2Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 3Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 4Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 5Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2
... Checks Eligibility for Medicaid, Child Health Plus, Family Health PlusTARRYTOWN, ... www.EnrollNY.org -- allows uninsured ... and -- for the first time -- connects users to ... to residents of New York City,s five boroughs and six ...
... May 7 Eclipsemed Ltd, a leading national ... AG, of Germany, a leading manufacturer of medical and aesthetic ... will be featured on the Lifetime Network,s The ... targeting women and women,s issues. The program will air on ...
... in First Quarter ResultsHARRISBURG, Pa., May 7 ... its 2009 community outreach program has provided more ... underserved in the first quarter of 2009."The tough ... for the uninsured community to seek the proper ...
... Neuromodulation , edited by Elliot S. Krames, P. ... is the first comprehensive and in-depth reference textbook covering ... by providing a complete discussion of the fundamental principles ... cord, peripheral nerves, autonomic nerves and various organs. The ...
... the FRAX Slide-kit, has been launched by the ... World Health Organization Collaborating Centre for Metabolic Bone ... can be downloaded free of charge from the ... The FRAX Slide-kit is intended as a teaching ...
... of the condition may decrease potential riskSCHAUMBURG, Ill., May ... as hyperhidrosis already have to deal with a number ... stains can make simple tasks such as shaking hands ... new study, people with primary hyperhidrosis also have a ...
Cached Medicine News:Health News:EnrollNY(TM): Easy Way for Uninsured New Yorkers to Find Free and Low-Cost Health Insurance 2Health News:Body-Jet(R), State of the Art Water-Jet Assisted Liposuction Technology to be Featured on Lifetime Television Network, The Balancing Act 2Health News:United Concordia Provides $100,000 in Free Dental Services 2Health News:Study Finds That Patients With Excessive Sweating Condition Are More Likely to Develop Skin Infections 2Health News:Study Finds That Patients With Excessive Sweating Condition Are More Likely to Develop Skin Infections 3
Fenestrated 14 mm blades and canthus bar. Adjustable blade locking screws on outside of branches. Dull finish....
Double bent ends prevent wire from catching when pushed forward. Designed for use with the Castroviejo Snare (E3675). Package of 12 stainless steel wires. Overall length 4.3 inches....
Replacement snares for the E3525. 3 per package....
... to be used only with the E3671 twisted ... turning the wing nut and the loop can ... by ratchet so that the loop can be ... Overall length - 5.6 inches. Comes with one ...
Medicine Products: